Table 3.
Clinical trials of therapeutic antibodies for COVID-19
| Target & mAb drug | ClinicalTrials.gov identification | Type | Phase |
|---|---|---|---|
| Anti-IL-6 | |||
| Clazakizumab | NCT04348500, 6 trials | Humanized rabbit IgG1 mAb | II |
| Siltuximab | NCT04329650, 3 trials | Chimeric IgGκ mAb | II/III |
| Olokizumab | NCT04452474, 2 trials | Humanized IgG4 mAb | II/III |
| Anti-IL-6R | |||
| Levilimab | NCT04397562 | Human mAb | III |
| Sarilumab | NCT04661527, 9 trials | Human IgG1 mAb | I/II/III |
| Sirukumab | NCT04380961 | Human IgG1κ mAb | II |
| Tocilizumab | NCT04372186, 56 trials | Humanized mouse IgG1 mAb | EUA |
| Anti-IL-1β | |||
| Canakinumab | NCT04362813, 5 trials | Human IgG1κ mAb | III |
| Anti-TNF | |||
| Infliximab | NCT04425538, 4 trials | Chimeric IgG1 mAb | II |
| Adalimumab | NCT04705844 | Human mAb | III |
| Anti-GM-CSF | |||
| Lenzilumab | NCT04351152 | Human IgG1 mAb | III |
| Otilimab | NCT04376684 | Human IgG1 mAb | II |
| TJ003234 | NCT04341116 | Human IgG1 mAb | II/III |
| Anti-GM-CSFR | |||
| Gimsilumab | NCT04351243 | Human IgG1 mAb | II |
| Anti-GM-CSFR-α | |||
| Mavrilimumab | NCT04447469, 5 trials | Human IgG4 mAb | II/III |
| Anti-C5 | |||
| Eculizumab | NCT04346797, 4 trials | Humanized mouse IgG2/4κ mAb | II |
| Anti-C5a | |||
| Vilobelimab | NCT04333420 | Chimeric IgG4 mAb | II/III |
| Anti-C5aR | |||
| Avdoralimab | NCT04371367, 2 trials | Human IgG1 mAb | II |
| Anti-PD-1 | |||
| Nivolumab | NCT04356508, 3 trials | Human IgG4 mAb | II |